A facility operated by Vancouver-based Zenabis Global Inc. failed an inspection to receive a key European Union certification last year, hindering the cannabis producer’s ability to ship medical cannabis to the continent.
Regulators in Malta published a "statement of non-compliance with GMP [good manufacturing practice]" against Zenabis Nov. 27 after determining that an inspection conducted on Dec. 16, 2018 at the company's facility in Delta, B.C. did not comply with the EU's GMP requirements.
GMP certification is widely known as the gold standard process for a company to be able to sell medical cannabis across the EU.
As a result of the non-compliance, the Maltese regulator said the sale, import, and distribution of any medical cannabis products made at Zenabis's Delta facility is prohibited in Malta, a move that will likely suspend the company's plans to export legal pot to Europe.
Read the full article at bnnbloomberg.ca